Quanterix Launches Multiplexed Single Molecule Immunoassay Technology to Improve Diagnosis and Potential Treatment of Complex Diseases

Quanterix Launches Multiplexed Single Molecule Immunoassay Technology to Improve Diagnosis and Potential Treatment of Complex Diseases

September 17, 2013

Simoa releases study on the first single molecule immunoassay capable of measuring multiple proteins at subfemtomolar concentrations

Visterra Announces an Oral Presentation of VIS410 Data that Showed Neutralization of H5 and H7 Influenza Strains with Pandemic Potential

Visterra Announces an Oral Presentation of VIS410 Data that Showed Neutralization of H5 and H7 Influenza Strains with Pandemic Potential

September 12, 2013

Preclinical results presented at ICAAC 2013 demonstrated the ability of VIS410 to neutralize influenza strains with pandemic potential, H5N1 and H7N9VIS410, a novel engineered human antibody against seasonal and pandemic flu, is advancing to the clinic in 2014

T2 Biosystems Announces direcT2 Pivotal Clinical Trial of T2Candida Enrolling at All Clinical Sites

T2 Biosystems Announces direcT2 Pivotal Clinical Trial of T2Candida Enrolling at All Clinical Sites

September 9, 2013

--T2Candida Directly Detects Species-specific Candida from Whole Blood in Approximately Three Hours--

Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential

Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential

September 9, 2013

Broadly protective properties of VIS410, a novel engineered human antibody, presented at the Options for the Control of Influenza conference in Cape Town, South Africa

CAMBRIDGE, Mass., Sep 09, 2013 (BUSINESS WIRE) -- Visterra, Inc., developer of novel therapeutics to treat major infectious diseases, today announced that its Chief Medical Officer, Donna Ambrosino, M.D., presented data on VIS410 at the Options for the Control of Influenza, an international conference held every three years, taking place this year in Cape Town, South Africa on September 5-9, 2013.

Study Published in Nature Biotechnology Demonstrates Ability of Moderna's Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue

Study Published in Nature Biotechnology Demonstrates Ability of Moderna's Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue

September 8, 2013

Messenger RNA therapeutics™ successfully induced high-level, transient expression of VEGF-A protein in the heart, stimulating the growth of cardiovascular cells and improving heart function and survival in an animal model of myocardial infarction

Syros Pharmaceuticals Appoints Vicki L. Sato, Ph.D., to Board of Directors

Syros Pharmaceuticals Appoints Vicki L. Sato, Ph.D., to Board of Directors

September 5, 2013

WATERTOWN, Mass., Sep 05, 2013 (BUSINESS WIRE) -- Syros Pharmaceuticals, a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, announced today the appointment of Vicki L. Sato, Ph.D., to its Board of Directors. Dr.

Flagship VentureLabs Launches Midori Renewables

Flagship VentureLabs Launches Midori Renewables

September 4, 2013

New Venture is Commercializing a Novel Catalytic Process to Convert Non-Food Biomass Into Sugar

Affinnova Reveals Bottle Design Trumps Taste in Vodka Brand War

Affinnova Reveals Bottle Design Trumps Taste in Vodka Brand War

September 4, 2013

Study Shows Package Design Plays Vital Role in Consumer Perception and Shelf Impact

Tetraphase Doses First Patient in Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections

Tetraphase Doses First Patient in Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections

September 3, 2013

- First of Two Planned Phase 3 Clinical Trials of Tetraphase's Lead Antibiotic Candidate Designed to Support Submission for Approval in Two Indications: Complicated Intra-abdominal Infections and Complicated Urinary Tract Infections -

The World Economic Forum Recognizes Four Flagship Ventures Portfolio Companies as Technology Pioneers for 2014

The World Economic Forum Recognizes Four Flagship Ventures Portfolio Companies as Technology Pioneers for 2014

August 28, 2013

Agios Pharmaceuticals, BIND Therapeutics, Oasys Water and Selecta Biosciences to be honored